It will rebound. Cytogen s products were marketed before the health organizations, insurance companies, government or physicians were ready for them. The products are promising and will be marketed appropriately. An experienced, efficient team that is determined to turn Cyto into a top-tier genomics firm has replaced the past management. Investors appreciate all the scientific disciplines of the firm.
Monoclonal antibodies rank second in the group classification.
Cyto is an expert in this domain having approved monoclonal antibody diagnostics, which are offering proof of safety and efficacy for the same products developed as therapeutics. Cytogen s proteomics technology, developed and totally owned by its subsidiary, AxCell, is a member of this group. In fact, it is a missing link that will contribute to technological advancement in drug discovery. PSMA is patented from top to bottom. Together with AxCell s technology, sublicensing to biotechs and pharmaceutical firms will bring in large revenues.